Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08PXR
|
||||
| Former ID |
DCL000315
|
||||
| Drug Name |
ABT-761
|
||||
| Synonyms |
Atreleuton; Atreleuton [USAN]; ABT 761; A-85761; Atreleuton (USAN/INN); 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Asthma [ICD10:J45] | Phase 3 | [1] | ||
| Company |
Abbott Laboratories
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H15FN2O2S
|
||||
| Canonical SMILES |
CC(C#CC1=CC=C(S1)CC2=CC=C(C=C2)F)N(C(=O)N)O
|
||||
| InChI |
1S/C16H15FN2O2S/c1-11(19(21)16(18)20)2-7-14-8-9-15(22-14)10-12-3-5-13(17)6-4-12/h3-6,8-9,11,21H,10H2,1H3,(H2,18,20)/t11-/m1/s1
|
||||
| InChIKey |
MMSNEKOTSJRTRI-LLVKDONJSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Arachidonate 5-lipoxygenase | Target Info | Inhibitor | [2], [3], [4] | |
| BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
| Resolvin D biosynthesis | |||||
| Leukotriene biosynthesis | |||||
| Lipoxin biosynthesis | |||||
| Aspirin triggered resolvin D biosynthesis | |||||
| Aspirin triggered resolvin E biosynthesis | |||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Toxoplasmosis | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| WikiPathways | Vitamin D Receptor Pathway | ||||
| Arachidonic acid metabolism | |||||
| Eicosanoid Synthesis | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71. | ||||
| REF 2 | Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307. | ||||
| REF 3 | N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorg Med Chem Lett. 1999 Apr 5;9(7):979-84. | ||||
| REF 4 | The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage. Neurosurgery. 2001 Nov;49(5):1205-12; discussion 1212-3. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.